Journal article icon

Journal article

A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial

Abstract:
Objective: To study the immunogenicity and reactogenicity of a combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine (Hib-MenC-TT) when administered as a booster dose in combination with a measles, mumps and rubella vaccine (MMR). Design: A phase 3 open randomised controlled trial. Setting: One centre in Oxford, Uk and nine centres in Poland. Subjects: 12-15-month-old healthy children. Interventions: In the primary state of the study 500 healthy 6-12-week-old infants were randomised in a 3:1 ratio to receive Hib-MenC-TT+DTPa-IPV or MenC-CRM197 vaccine+DTPa-IPV-Hib. In the booster stage, 476 participants (190 in the UK and 286 in Poland) were vaccinated with Hib-MenC-TT and MMR. Main outcome measures: The proportion of children with protective serum antibody levels against MenC and Hib 6 weeks following a Hib-MenC-TT booster dose. Results: The co-primary objectives were met: the Hib-MenC-TT booster dose induced protective antibody titres in children vaccinated with Hib-MenC-TT+DTPa-IPV or MenC-CRM197+DTPa-IPV-Hib at 2, 3 and 4 months of age. 94.8% (lower limit of (LL) 95% CI 92.4) of participants had rSBA-MenC ≥1:128 and 100% (LL95% CI 99.2) achieved anti-PRP concentrations ≥ 1.0 μg/ml. The percentage of toddlers with a post boost rSBA-MenC of 1:128 was significantly higher after priming with Hib-MenC-TT (97.7%) than after MenC-CRM197 (86%) difference: 11.7%; 95% CI 6.2 to 19.4). Conclusion: The waning antibody titres against Hib and MenC following primary immunisation can be boosted to protective levels by administering the Hib-MenC-TT vaccine at 12-15 months of age, supporting the recent introduction of this vaccine in the UK immunisation schedule to sustain protection of children against Hib and MenC disease.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Publisher copy:
10.1136/adc.2007.136036

Authors

More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Paediatrics
Research group:
Oxford Vaccine Group
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Paediatrics
Research group:
Oxford Vaccine Group
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Paediatrics
Research group:
Oxford Vaccine Group
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Paediatrics
Research group:
Oxford Vaccine Group
Role:
Author
More by this author
Institution:
University of Oxford
Department:
Centre for Statistics in Medicine
Role:
Author


Publisher:
BMJ Publishing Group
Journal:
Archives of Disease in Childhood More from this journal
Volume:
93
Issue:
11
Pages:
963-970
Publication date:
2008-11-01
DOI:
EISSN:
14682044


Language:
English
Subjects:
UUID:
uuid:180f47fd-9277-4b1d-a7e5-d13f038df2da
Local pid:
ora:3181
Deposit date:
2009-12-21
ARK identifier:

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP